Literature DB >> 24090471

Circulating angiogenic biomolecules at rest and in response to upper-limb exercise in individuals with spinal cord injury.

Angelo V Vasiliadis, Andreas Zafeiridis, Konstantina Dipla, Nikiforos Galanis, Dimitrios Chatzidimitriou, Antonios Kyparos, Michalis G Nikolaidis, Ioannis S Vrabas.   

Abstract

OBJECTIVE: Individuals with spinal cord injury (SCI) show structural and functional vascular maladaptations and muscle loss in their lower limbs. Angiogenic biomolecules play important roles in physiological and pathological angiogenesis, and are implicated in the maintenance of muscle mass. This study examined the responses of angiogenic molecules during upper-limb aerobic exercise in patients with SCI and in able-bodied (AB) individuals.
METHODS: Eight SCI patients with thoracic lesions (T6-T12, ASIA A) and eight AB individuals performed an arm-cranking exercise for 30 minutes at 60% of their VO2max. Plasma concentrations of vascular endothelial growth factor (VEGF-A165), VEGF receptor 1 (sVEGFr-1), VEGF receptor 2 (sVEGFr-2), metalloproteinase 2 (MMP-2), and endostatin were measured at rest, after exercise, and at 1.5 and 3.0 hours during recovery.
RESULTS: The two-way analysis of variance showed non-significant main effects of "group" and significant main effects of "time/exercise" for all angiogenic biomolecules examined (P < 0.01-0.001). The arm-cranking exercise significantly increased plasma concentrations of VEGF, sVEGFr-1, sVEGFr-2, MMP-2, and endostatin in both groups (P < 0.001-0.01). The magnitude of the increase was similar in both patients with SCI and AB individuals, as shown by the non-significant group × time interaction for all angiogenic parameters.
CONCLUSIONS: Upper-limb exercise (arm-cranking for 30 minutes at 60% of VO2max) is a sufficient stimulus to trigger a coordinated circulating angiogenic response in patients with SCI. The response of angiogenic molecules to upper-limb aerobic exercise in SCI appears relatively similar to that observed in AB individuals.

Entities:  

Keywords:  Angiogenesis; Arm exercise; Endostatin; Exercise; Metalloproteinase; Spinal cord injury; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2013        PMID: 24090471      PMCID: PMC4066432          DOI: 10.1179/2045772313Y.0000000141

Source DB:  PubMed          Journal:  J Spinal Cord Med        ISSN: 1079-0268            Impact factor:   1.985


  53 in total

1.  Exercise increases soluble vascular endothelial growth factor receptor-1 (sFlt-1) in circulation of healthy volunteers.

Authors:  Amelia Purser Bailey; Megan Shparago; Jian-Wei Gu
Journal:  Med Sci Monit       Date:  2006-01-26

2.  Assessment of autonomic dysfunction following spinal cord injury: rationale for additions to International Standards for Neurological Assessment.

Authors:  Andrei V Krassioukov; Ann-Katrin Karlsson; Jill M Wecht; Lisa-Ann Wuermser; Christopher J Mathias; Ralph J Marino
Journal:  J Rehabil Res Dev       Date:  2007

3.  Sympathetic control of VEGF angiogenic signaling: dual regulations by alpha 2-adrenoceptor activation?

Authors:  Yuichi Hattori; Seiji Yamamoto; Naoyuki Matsuda
Journal:  Circ Res       Date:  2007-09-28       Impact factor: 17.367

4.  Rapid vascular adaptations to training and detraining in persons with spinal cord injury.

Authors:  Dick H Thijssen; Reinier Ellenkamp; Paul Smits; Maria T Hopman
Journal:  Arch Phys Med Rehabil       Date:  2006-04       Impact factor: 3.966

5.  Effect of training on the response of plasma vascular endothelial growth factor to exercise in patients with peripheral arterial disease.

Authors:  Rachel E Wood; Brad E Sanderson; Christopher D Askew; Philip J Walker; Simon Green; Ian B Stewart
Journal:  Clin Sci (Lond)       Date:  2006-12       Impact factor: 6.124

6.  Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells.

Authors:  Eric V Yang; Anil K Sood; Min Chen; Yang Li; Tim D Eubank; Clay B Marsh; Scott Jewell; Nicholas A Flavahan; Carl Morrison; Peir-En Yeh; Stanley Lemeshow; Ronald Glaser
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

7.  Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise.

Authors:  James W Ji; Feilim Mac Gabhann; Aleksander S Popel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-09-21       Impact factor: 4.733

8.  Acute resistance exercise increases skeletal muscle angiogenic growth factor expression.

Authors:  T P Gavin; J L Drew; C J Kubik; W E Pofahl; R C Hickner
Journal:  Acta Physiol (Oxf)       Date:  2007-06-12       Impact factor: 6.311

9.  Effects of short-term vibration and hypoxia during high-intensity cycling exercise on circulating levels of angiogenic regulators in humans.

Authors:  Frank Suhr; Klara Brixius; Markus de Marées; Birgit Bölck; Heinz Kleinöder; Silvia Achtzehn; Wilhelm Bloch; Joachim Mester
Journal:  J Appl Physiol (1985)       Date:  2007-04-19

10.  Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome.

Authors:  Giuseppe Derosa; Angela D'Angelo; Filippo Scalise; Maria A Avanzini; Carmine Tinelli; Emmanouil Peros; Elena Fogari; Arrigo F G Cicero
Journal:  Heart Vessels       Date:  2007-11-26       Impact factor: 2.037

View more
  3 in total

1.  Absence of cardiovascular drift during prolonged arm-crank exercise in individuals with spinal cord injury.

Authors:  Masahiro Horiuchi; Yoshiyuki Fukuoka
Journal:  Spinal Cord       Date:  2019-06-04       Impact factor: 2.772

Review 2.  Physiological Capillary Regression is not Dependent on Reducing VEGF Expression.

Authors:  I Mark Olfert
Journal:  Microcirculation       Date:  2016-02       Impact factor: 2.628

Review 3.  Targeting miR-21 in spinal cord injuries: a game-changer?

Authors:  Amir Mohammad Malvandi; Seyed Hamidreza Rastegar-Moghaddam; Saeede Ebrahimzadeh-Bideskan; Giovanni Lombardi; Alireza Ebrahimzadeh-Bideskan; Abbas Mohammadipour
Journal:  Mol Med       Date:  2022-09-23       Impact factor: 6.376

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.